EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 374 filers reported holding EXELIXIS INC in Q2 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,273,855 | -71.0% | 58,300 | -69.6% | 0.00% | -69.2% |
| Q1 2022 | $4,389,000 | +411.5% | 191,800 | +404.7% | 0.01% | +550.0% |
| Q1 2021 | $858,000 | +21.0% | 38,000 | -5.0% | 0.00% | -33.3% |
| Q4 2019 | $709,000 | -19.4% | 40,000 | -19.2% | 0.00% | 0.0% |
| Q3 2019 | $880,000 | -37.0% | 49,500 | -23.8% | 0.00% | 0.0% |
| Q2 2019 | $1,396,000 | +126.6% | 65,000 | +133.6% | 0.00% | – |
| Q1 2018 | $616,000 | -31.1% | 27,830 | -24.7% | 0.00% | -100.0% |
| Q3 2017 | $894,000 | +1017.5% | 36,943 | +255.7% | 0.00% | – |
| Q2 2016 | $80,000 | -69.3% | 10,386 | -77.6% | 0.00% | -100.0% |
| Q3 2015 | $261,000 | -66.9% | 46,437 | -79.9% | 0.00% | – |
| Q2 2014 | $788,000 | -16.4% | 230,970 | -12.5% | 0.00% | – |
| Q1 2014 | $943,000 | +388.6% | 264,056 | +697.8% | 0.00% | -100.0% |
| Q3 2013 | $193,000 | -77.1% | 33,100 | -82.1% | 0.00% | -88.9% |
| Q4 2012 | $844,000 | – | 184,850 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |